Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00496262 · ClinicalTrials.gov registry record · Phase 2
Human Fibrinogen - Pharmacokinetics
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00496262 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 15 participants.
The verdict
NCT00496262, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness \[MCF\]) in subjects with congenital fibrinogen deficiency. MCF was measured to demonstrate the functional activity of replacement fibrinogen when a fixed dose of human fibrinogen concentrate was administered.
Interventions
- BIOLOGICAL Human Fibrinogen Concentrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00496262
The ClinicalTrials.gov registry entry for NCT00496262 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human Fibrinogen Concentrate is the first listed.
NCT00496262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00496262 about?
NCT00496262 is a clinical study titled "Human Fibrinogen - Pharmacokinetics". This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness \[MCF\]) in subjects with congenital fibrinogen deficiency. MCF was measured to demonstrate the functional activity of replacement fibrinogen when a fixed dose of human fibr...
What is the current status of trial NCT00496262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-07. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00496262?
The interventions under investigation include: Human Fibrinogen Concentrate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00496262?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.